TITLE:
Nutraceutical Treatment of Patients with Polycystic Ovary Syndrome
AUTHORS:
Comhaire Frank, Decleer Wim
KEYWORDS:
Polycystic Ovary Syndrome
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.11 No.9,
September
8,
2021
ABSTRACT: Polycystic Ovary Syndrome (PCOS) is a common cause of infertility,
requiring antioestrogen and, possibly, gonadotropin treatment for the induction
of ovulation. However, patients suffering
from this disease need long-term treatment since PCOS is associated with
an increased risk of metabolic syndrome, hyperinsulinemia, oxidative stress,
inflammation, cardiovascular disease, and cancer. Allopathic treatment includes
the continuous use of oral contraceptives, preferentially with complementary
anti-androgen activity, and metformin. However, these treatments only partially
correct all aspects of the disease, while carrying potential adverse effects per
se. Complementary and alternative medicine (CAM) offers opportunities for
treatment through the use of nutraceuticals containing plant extracts,
minerals, and vitamins with antioxidant, anti-inflammatory, and adaptogen
capacity, as well as for correcting insulin resistance. Here we justify the
formulation of the nutraceutical QALY® (Jona Pharma, Elversele, Belgium) that
is composed of Ubiquinone Q10, the vitamins B9 and B12, the salts of zinc and
selenium, the biomass of Haematococcus
pluvialis, and the extracts of Mediterranean pine bark and of Rhodiola rosea. This can be complemented
by phytotherapy with the extract of Momordica
charantia plus alfa lipoic acid (Momordica plus®).